From Tumor Biology to Therapeutic Design: Expert Insights from Vector Laboratories
Two Vector scientists were recently interviewed about glycosylation in cancer research and advances in bioconjugation for next-generation therapeutics.
Vector Laboratories’ blog provides a wealth of information on immunohistochemistry (IHC), immunofluorescence (IF), and related life science research topics.
Two Vector scientists were recently interviewed about glycosylation in cancer research and advances in bioconjugation for next-generation therapeutics.
Vector Laboratories will be attending Cancer Glyco-X 2026 to discuss how the right tools reveal glyco-insights in cancer research. Product Manager Shuhui Chen and Sr. Field Application Scientist Sabrina Mateos will be representing Vector Laboratories... Read more
Immune checkpoint therapy describes a class of antibody therapeutics for the treatment of cancer that target proteins that modulate immune responses. More than a dozen approved therapeutics target immune checkpoint proteins like PD-1, PD-L1, and... Read more
Looking Beyond Genes and Proteins Genomics has transformed how we identify disease, and proteomics has expanded how we understand function. But in Congenital Disorders of Glycosylation (CDGs), neither tells the full story. CDGs arise from... Read more
Probing protein glycosylation uncovers new diagnostic and therapeutic avenues for breast cancer, one of the most common forms of cancer.
Alzheimer’s Disease is complex disease on the rise worldwide. Glycosylation is critical to every facet of disease mechanisms and treatments.
Vector has been highly commended for the 2026 CiteAb Innovation Award, recognizing the impact of the Glysite Explorer in advancing glycosylation research.
Glycosylation is an understudied but critical component of colon carcinoma. The right tools aid in cancer research, diagnosis, and treatment.
Protein glycosylation is ubiquitous yet overlooked. Learn how Vector's suite of tools bring protein glycosylation insights to researchers across fields.